Key result
Greater pericardial adipose tissue linked to ~62% higher severe SARS-CoV-2 risk per doubling, independent of BMI.
Why the study?
BMI increases risk of severe SARS-CoV-2 infection but is imprecise and fails to account for adipose tissue distribution, leaving it unclear whether specific CT-measured adipose depots associate with hospitalization or death.
Does greater CT-measured adipose tissue increase the risk of hospitalization or death from SARS-CoV-2 in adults?
Cohort (n=8,412)
Yes
Does greater CT-measured adipose tissue increase the risk of hospitalization or death from SARS-CoV-2 in adults?
Effect estimate: HR 1.62 (95% CI 1.25-2.09)
CT-measured pericardial and abdominal visceral adiposity are associated with increased risk of severe SARS-CoV-2 infection, independent of BMI and clinical cardiometabolic comorbidities.
CT adiposity measures were associated with higher COVID-19 hospitalization risk independent of BMI; extends BMI literature but leaves open causality and intervention targets.
Background Higher body mass index (BMI) increases risk of respiratory failure and death from SARS-CoV-2 infection. BMI is imprecise and fails to account for adipose tissue distribution. We sought to determine whether pericardial adipose tissue (PAT), abdominal visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), or hepatic adipose deposition on pre-pandemic computed tomography (CT) scans associate with increased risk of hospitalization or death from SARS-CoV-2. Methods The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) ascertained SARS-CoV-2 outcomes among participants from 14 US-based cohort studies. This analysis includes participants enrolled in the Jackson Heart, CARDIA, MESA, and Framingham Heart studies. C4R attempted to enroll all cohort participants who were alive on March 1, 2020 and had not withdrawn consent for cohort participation. Our primary exposure was adipose depot size measured on research CT scans performed between 2000 and 2011. Our primary outcome was time from March 1, 2020 to hospitalization or death from SARS-CoV-2 infection ascertained by self-report or active surveillance and confirmed when available, by protocolized record review. Results There were 8412 participants with at least one CT adipose measure, among whom 184 events occurred over a median (interquartile range) of 547 (338–609) days. In adjusted models, both higher PAT (per doubling in PAT, HR 1.62, 95% CI 1.25–2.09) and higher VAT (per 1-standard deviation, HR.41, 95% CI 1.20–1.67) associated with greater hazards of hospitalization or death from SARS-CoV-2. Associations remained after adjustment for BMI, diabetes, cardiovascular disease, hypertension, and waist circumference. SAT was associated with hospitalization or death but not after adjustment for BMI and obesity complications. Hepatic adipose deposition was not associated with hospitalization or death. Conclusion Greater CT-measured pericardial and abdominal visceral adipose tissue were associated with increased hazards of hospitalization or death from SARS-CoV-2 independent of BMI and clinical cardiometabolic comorbidities. Further research should investigate use of CT adipose measures to quantify risk of severe disease from viral infections and to investigate mechanisms linking adiposity to lung injury.
No takes yet. Share an insight, caveat, or question.
Al‐Naamani et al. (2026) conducted a cohort in SARS-CoV-2 infection (n=8,412). Higher pericardial adipose tissue (PAT) on pre-pandemic CT vs. Lower pericardial adipose tissue was evaluated on Time to hospitalization or death from SARS-CoV-2 infection (HR 1.62, 95% CI 1.25-2.09). Greater CT-measured pericardial adipose tissue was associated with a 62% increased hazard of hospitalization or death from SARS-CoV-2 per doubling of volume, independent of BMI and comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: